Concepedia

Colin Hessel

CH

23

Publications

7.6K

Citations

20

H-Index

1997

Active since

Affiliations

Exelixis (United States)(Current)

Memorial Sloan Kettering Cancer Center

Massachusetts General Hospital

Washington University in St. Louis

University of Ulsan

Colin Hessel is an author at Exelixis (United States) specializing in medicine, cancer therapeutics, and oncology.

ORCID

Top concepts

Publications per year

1997–2023

23

Publications

23

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng et al. · New England Journal of Medicine · 2018 · 2.3K citations · Full text

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · New England Journal of Medicine · 2015 · 1.2K citations · Full text

Cabozantinib in Progressive Medullary Thyroid Cancer

Rossella Elisei, Martin Schlumberger, Stefan Müller et al. · Journal of Clinical Oncology · 2013 · 1.2K citations · Full text

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · The Lancet Oncology · 2016 · 927 citations · Full text

, , +8

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Toni K. Choueiri, Colin Hessel, Susan Halabi et al. · European Journal of Cancer · 2018 · 392 citations · Full text

Rows per page

1–5 of 23